Chandigarh University, Uttar Pradesh gets PCI nod to launch pharmacy courses

IMT News Desk
IMT News Desk
· 2 min read

School of Pharmacy, Chandigarh University, Uttar Pradesh has received formal approval from the Pharmacy Council of India (PCI) for its Bachelor of Pharmacy (B. Pharma) programme

The School of Pharmacy at CU Uttar Pradesh has been conceptualised with a future-ready educational model aligned with industry demands and driven by cutting-edge technology. The curriculum is designed to balance theoretical foundations with hands-on training, ensuring that students graduate as competent and industry-ready healthcare professionals. The Pharmacy Council of India has granted formal approval to Chandigarh University, Lucknow Campus to begin offering 60 seats in the Pharmacy course from the academic session 2025.

The School of Pharmacy offers an infrastructure tailored for advanced research. Students actively participate in projects related to pharmacokinetics, clinical pharmacy, medicinal chemistry, and toxicology. The curriculum has been crafted in collaboration with international industry experts and academicians, enabling students to grasp both traditional and emerging subjects with clarity while sharpening their skills in line with global standards.

Students at the School of Pharmacy can pursue careers in diverse fields such as Clinical Research, Intellectual Property Management, Regulatory Affairs, Quality Control, and Medical Writing. The university also imparts regulatory training in Good Manufacturing Practices (GMP), Good Laboratory Practices (GLP), and Good Clinical Practices (GCP), ensuring graduates are prepared to work in highly regulated environments.

Chandigarh University, Uttar Pradesh, stands as a model of integrated education where learning, technology, and industry interface seamlessly. Students not only receive rigorous academic instruction but also benefit from industry training, internships, and research exposure, preparing them for a balanced and successful career.

The university’s AI-supported, modern campus in Unnao—backed by industry-aligned curriculum, advanced labs, and seasoned faculty—provides a solid academic foundation. Strategic partnerships with leading companies and government bodies further enhance student opportunities by offering essential skill training and diverse career pathways.

Read Next

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk
DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 
News
June 11, 2026

DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 

DFE Pharma has earned its third consecutive Gold Medal from EcoVadis, the world leader in corporate sustainability assessments, in recognition of its strong performance in the four themes rated: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. This distinction places DFE Pharma in the top 5% of companies, reflecting the company’s focused efforts to […]
Article by: IMT News Desk
Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India
News
June 11, 2026

Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India

Oval Advanced Fertility Care and Merck Specialities Private Limited, the Indian healthcare arm of Merck KGaA, Darmstadt, Germany and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MOU).   India’s IVF market, valued at approximately USD 2.35 billion in 2024, is projected […]
Article by: IMT News Desk
Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global
News
June 11, 2026

Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global

Bengaluru-based precision oncology startup 4baseCare has raised ₹128 crore in its ongoing Series B funding round to expand its hospital-linked genomics laboratory network globally and scale its AI-powered precision oncology platform, OncoTwin. The latest funding round, which follows a first close of ₹90 crore co-led by Ashish Kacholia and Lashit Sanghvi with participation from existing […]
Article by: IMT News Desk